BR112020013236A2 - proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso - Google Patents

proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso

Info

Publication number
BR112020013236A2
BR112020013236A2 BR112020013236-5A BR112020013236A BR112020013236A2 BR 112020013236 A2 BR112020013236 A2 BR 112020013236A2 BR 112020013236 A BR112020013236 A BR 112020013236A BR 112020013236 A2 BR112020013236 A2 BR 112020013236A2
Authority
BR
Brazil
Prior art keywords
immunomodulatory proteins
proteins
methods
immunomodulatory
infectious agents
Prior art date
Application number
BR112020013236-5A
Other languages
English (en)
Inventor
Ryan Swanson
Original Assignee
Alpine Immune Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences, Inc. filed Critical Alpine Immune Sciences, Inc.
Publication of BR112020013236A2 publication Critical patent/BR112020013236A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

A presente invenção refere-se a proteínas imunomoduladoras de múltiplos domínios, ácidos nucleicos que codificam essas proteínas imunomoduladoras, células projetadas para expressar as proteínas imunomoduladoras e agentes infecciosos contendo ácido nucleico que codifica as proteínas imunomoduladoras. As proteínas imunomoduladoras ligam tanto um receptor inibidor quanto um receptor envolvido nas cascatas de sinalização de ativação em uma célula imune, tal como uma célula T. As proteínas imunomoduladoras, as células projetadas e os agentes infecciosos fornecem utilidade terapêutica para uma variedade de doenças ou condições imunológicas. Composições e métodos para a produção e uso de tais proteínas são fornecidos.
BR112020013236-5A 2018-01-03 2019-01-03 proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso BR112020013236A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862613378P 2018-01-03 2018-01-03
US62/613,378 2018-01-03
US201862733622P 2018-09-19 2018-09-19
US62/733,622 2018-09-19
PCT/US2019/012222 WO2019136179A1 (en) 2018-01-03 2019-01-03 Multi-domain immunomodulatory proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112020013236A2 true BR112020013236A2 (pt) 2020-12-01

Family

ID=65409474

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020013236-5A BR112020013236A2 (pt) 2018-01-03 2019-01-03 proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso

Country Status (7)

Country Link
US (1) US20230101432A1 (pt)
EP (1) EP3735417A1 (pt)
AU (1) AU2019205273B2 (pt)
BR (1) BR112020013236A2 (pt)
CA (1) CA3087149A1 (pt)
SG (1) SG11202006148UA (pt)
WO (1) WO2019136179A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107969128A (zh) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) * 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2102623C (en) 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69534702T2 (de) 1994-09-23 2006-08-24 The University Of British Columbia, Vancouver Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
EP1016418B1 (en) 1994-10-03 2009-12-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
DE60107203T3 (de) 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
EP1461073B1 (en) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptide agonists of prostate-specific antigen, and uses therefor
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2007030803A2 (en) 2005-09-09 2007-03-15 Zymogenetics, Inc. Method for preparing trimeric proteins
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
EP3342872A1 (en) 2007-12-11 2018-07-04 The University of North Carolina at Chapel Hill Polypurine tract modified retroviral vectors
EP3936122A1 (en) 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
WO2013130684A1 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
CA2903546A1 (en) 2013-03-15 2014-09-25 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2014198002A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute A bacterium producing an interferon binding protein and uses thereof
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
AU2015343048A1 (en) * 2014-11-06 2017-05-18 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
EP3020816A1 (en) 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
CN107969128A (zh) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
JP2018534245A (ja) * 2015-09-14 2018-11-22 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
KR20190006495A (ko) * 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도

Also Published As

Publication number Publication date
CA3087149A1 (en) 2019-07-11
AU2019205273B2 (en) 2024-04-04
EP3735417A1 (en) 2020-11-11
US20230101432A1 (en) 2023-03-30
SG11202006148UA (en) 2020-07-29
AU2019205273A1 (en) 2020-07-16
WO2019136179A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
BR112020013236A2 (pt) proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112018070934A2 (pt) proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
BR112019006384A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
BR112016024579A2 (pt) métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva
BR112016023500A2 (pt) método e composições para imunoterapia celular
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
BR112017003505A2 (pt) anticorpos e receptores de antígeno quiméricos específicos para cd19
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BR112017017884A2 (pt) switches transcricionais desencadeados por ligação e métodos de uso dos mesmos
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
AR090158A1 (es) Polipeptidos de union a cx3cr1
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
WO2014066744A3 (en) Anti-complement c1s antibodies and uses thereof
MX2021010668A (es) Proteinas de fusion de citoquinas.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]